Prognostic significance of lncRNA DANCR expression in human cancers: a systematic review and meta-analysis

Liu, Wei; Wang, Qin-Peng; Guo, Jia

doi:10.1042/bsr20181627

Cited by 8 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We attempted to use mRNA data, LncRNA data and clinical follow-up data from the tumor genome atlas to identify LncRNA related to GBM prognosis and provide potential therapeutic targets for treatment. lncRNAs have become novel biomarkers for the diagnosis and prognosis of various human cancers [33][34][35][36]. We speculated that the differential expression of lncRNAs might be used as biomarkers to determine the prognosis of GBM patients, and previous studies have shown that several lncRNAs, including MEG3, H19 and Gas5, are abnormally expressed in all GBM patients [37][38][39][40].…”

Section: Discussionmentioning

confidence: 99%

Expression of lncRNAs Associated with GPCRs and Clinical Prognosis in GBM

Wang

Xiang

2021

Preprint

View full text Add to dashboard Cite

Background: Glioblastoma (GBM) is a primary malignant tumor of the central nervous system with a poor prognosis. Long non-coding RNAs (lncRNAs) play a variety of key regulatory roles in a variety of biological processes, and have an important influence on the occurrence and development of tumors by regulating the expression of target genes. However, their role in the prognosis of GBM is still lacking in accurate prognostic markers.This study aims to establish an effective lncRNAs model to evaluate the prognosis of GBM.Methods: We used data of mRNA, lncRNA and clinical follow-up from The Cancer Genome Atlas (TCGA) to conduct univariate analysis, clustering analysis, coding gene difference analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and Gene Ontology (GO) analysis for GBM patients. lncRNAs that are closely related to the survival and prognosis of GBM were found and a multiple regression model was constructed to calculate the risk score of the samples, so as to accurately predict the clinical prognosis of GBM patients.Results: Through multiple systematic analysis, we found 5 lncRNAs that are closely related to the survival and prognosis of GBM, and these 5 lncRNAs can be used as independent prognostic factors. Through GO enrichment analysis and KEGG pathway analysis, we found that there is a close relationship between GBM and G protein coupled receptors. Therefore, 93 mRNAs associated with G-protein-coupled receptors and 5 lncRNAs associated with independent prognostic factors were selected to calculate the correlation, respectively. In other words, a tumor-specific lncRNAs/mRNAs co-expression network was constructed through biological prediction based on correlation analysis. The results showed that lncRNAs and mRNAs interregulated very closely in GBM patients. In addition, we also constructed a multiple regression model with these 5 lncRNAs which was able to calculate the risk score of each sample to accurately predict the clinical prognosis of GBM patients.Conclusion: Our study found lncRNAs independently were related to the prognosis of GBM, and successfully constructed a multiple regression model related to lncRNAs, providing a new perspective for better evaluation of the role of lncRNAs in the clinical prognosis of GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of lncRNAs Associated with GPCRs and Clinical Prognosis in GBM

Wang

Xiang

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…SNHG13, a lncRNA also known as differentiation antagonizing non-protein coding RNA (DANCR), plays a regulatory role as an oncogene in multiple human cancers. DANCR expression is correlated with pathogenesis and progression and is predictive of the outcome of several neoplasms (38,39). PCa studies have indicated that DANCR may affect the treatment response to chemotherapy.…”

Section: Lncrna Snhgs In Prostate Cancermentioning

confidence: 99%

Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers

Yang

Zheng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The incidence of urological cancer has been gradually increasing in the last few decades. However, current diagnostic tools and treatment strategies continue to have limitations. Substantial evidence shows that long noncoding RNAs (lncRNAs) play essential roles in carcinogenesis and the progression, treatment response and prognosis of multiple human cancers, including urological cancers, gastrointestinal tumours, reproductive cancers and respiratory neoplasms. LncRNA small nucleolar RNA host genes (SNHGs), a subgroup of lncRNAs, have been found to be dysregulated in tumour cell biology. In this review, we summarize the impacts of lncRNA SNHGs in urological malignancies and the underlying mechanisms.

show abstract

“…Long non-coding RNAs (LncRNAs) represent the prevalent types of RNA molecules, typically exceeding 200 bp in size 32 ; 33 . Although they are unable to encode proteins, accumulating evidence has highlighted their critical role in regulating immune responses against cancer 32 ; 34 ; 35 . Through their functions, lncRNAs have signi cantly contributed to elucidating the complex molecular pathways that underlie cancer immunity and could be employed as novel therapeutic targets for cancer immunotherapy [36][37][38] .…”

Section: Introductionmentioning

confidence: 99%

Identifying Novel Necroptosis-Related Long Non-Coding RNAs: Prognostic and Immunotherapeutic Implications for Head and Neck Squamous Cell Carcinoma

Yin,

Chen,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Necroptosis could be a trigger and amplifier of anti-tumor immunity in cancer therapy. LncRNAsare vital in controlling immune system gene expression. We designed to establish a NRlncRNA signature for evaluation and prognosis prediction in HNSCC, ultimately providing a new perspective for clinical application. Materials and methods We acquired RNA-seq and clinical data for HNSCC and 67 NRGs. Subsequently, diverse analytical methods were utilized to discern predictive NRlncRNAs, calculate the risk score, and construct a meticulous risk evaluation model. Furthermore, the predictive capability of the risk model was confirmed through survival analysis, ROC curves, PCA, DCA, C-index, and nomograms. We endeavored to discern disparities among distinct cohorts concerning clinical characteristics, the infiltration of immune cells, the sensitivity to pharmaceutical agents, as well as molecules associated with immune response. Results A risk signature for 12 NRlncRNAs was developed, and the signature had high sensitivity and specificity in predicting survival rates. The established model exhibited a strong association with both survival outcomes and clinical features. Notably, the low-risk group demonstrated a substantially elevated survival probability and displayed a significant positive correlation with diverse immune cell infiltrations. Lastly, we selected different clinical drug regimens based on the different risk groups. Conclusion A prognostic model of NRlncRNAs has been developed for HNSCC that enables the estimation of the TME and the response to cancer immunotherapy. The model also has the potential to predict the prognosis, which may pave the way for novel clinical applications.

show abstract

Prognostic significance of lncRNA DANCR expression in human cancers: a systematic review and meta-analysis

Cited by 8 publications

References 36 publications

Expression of lncRNAs Associated with GPCRs and Clinical Prognosis in GBM

Expression of lncRNAs Associated with GPCRs and Clinical Prognosis in GBM

Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers

Identifying Novel Necroptosis-Related Long Non-Coding RNAs: Prognostic and Immunotherapeutic Implications for Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About